A common gut bacterium may help keep arteries clear, according to a new study published in Nature on October 7, 2026. Researchers led by a team at Sun Yat-sen University in Shenzhen, China, report that the gut microbe Bacteroides uniformis and a fatty acid it produces reduced artery plaque in mice prone to heart disease. The work adds to growing evidence of a gut microbe–heart disease connection, though the key results so far come from animals, not people.
Primary source: Yin, C. et al. “A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice,” Nature (published online October 7, 2026). DOI: 10.1038/s41586-026-11142-x.
Key Findings at a Glance
- The microbe: Bacteroides uniformis was often depleted in the gut microbiomes of people with cardiovascular disease, according to Nature‘s news coverage of the study.
- The molecule: The researchers identified pentadecanoic acid (PA, also written C15:0), an odd-chain saturated fatty acid, as a main active compound made by the bacterium.
- The effect in mice: PA supplementation reduced atherosclerotic plaque burden by about 50% and improved blood lipid profiles, according to the paper’s abstract.
- The mechanism: PA appears to directly inhibit HMG-CoA reductase, the liver enzyme that statin drugs also target, which lowers cholesterol production and increases LDL receptors that clear “bad” cholesterol from the blood.
- The human signal: PA levels were markedly lower in people with dyslipidaemia (abnormal blood fats). This finding is observational.
How the Gut Microbe–Heart Disease Study Was Done
Step 1: Comparing human gut microbiomes
The team analysed stool samples from people with and without cardiovascular disease and found that B. uniformis was frequently less abundant in those with heart disease. The paper’s data section cites public human metagenomic datasets (PRJNA615842 and PRJEB21528).
Step 2: Testing the bacterium in mice
Researchers used mice genetically engineered to develop atherosclerosis, the build-up of fatty plaque in artery walls, and fed them a high-fat diet. Mice given live B. uniformis developed smaller plaques in their main arteries than untreated mice. Nature‘s news report says the bacterium reduced plaque by roughly one-third, while the paper’s abstract reports a reduction of about 50% with PA supplementation. Treated mice also had lower total and LDL cholesterol and fewer inflammatory immune cells in their artery walls.
Step 3: Finding the active molecule
Using bioactivity-guided screening, the team isolated pentadecanoic acid as a key bioactive metabolite. A survey of 100 gut bacterial strains found that PA production occurs across multiple genera in the Bacteroidota group, not just in B. uniformis.
Step 4: Checking human samples
To test whether the findings might apply to people, the researchers examined blood and stool samples from more than 200 human donors. People with abnormally high blood fats had lower PA levels than healthy controls, and people with heart disease carried fewer bacterial genes for producing the molecule, Nature reported.
Why It Matters
Atherosclerosis underlies most heart attacks and many strokes. Statins, the most widely used cholesterol-lowering drugs, work by blocking HMG-CoA reductase. The finding that a bacterial product appears to act on the same enzyme suggests the gut microbiome may influence cholesterol in a way that is similar, at least in mice, to a well-established drug class.
| Item | What the study reports |
|---|---|
| Organism | Bacteroides uniformis (gut bacterium) |
| Active molecule | Pentadecanoic acid (C15:0) |
| Target | HMG-CoA reductase (same enzyme targeted by statins) |
| Mouse result | ~50% less plaque with PA supplementation (abstract) |
| Human evidence | Lower PA in people with dyslipidaemia; observational only |
Who Is Affected
- People at risk of heart disease could eventually benefit if microbiome-based approaches prove safe and effective in human trials. No such trial results have been reported.
- Researchers and drug developers working on probiotics, “live biotherapeutics,” and cholesterol drugs gain a new candidate pathway to investigate.
- Clinicians should note that the findings do not change current treatment guidance.
What Experts Say
Expert commentary: Ben Chen, a cardiovascular specialist at the Monash Victorian Heart Institute in Melbourne, Australia, who was not involved in the study, told Nature that the work provides “valuable evidence that the gut microbiome can influence vascular health.”
Author view (paraphrased by Nature): Co-author Wenjing Zhao, a microbiologist at Sun Yat-sen University, said the findings point to new ways the gut microbiome might be harnessed to protect the heart.
Limitations
- Mouse data: The plaque-reduction results come from genetically engineered mice on a high-fat diet. Results in mice often do not carry over to people.
- Observational human data: Lower PA levels in people with high blood fats show an association, not cause and effect.
- Reported figures vary: Nature‘s news article describes the bacterium’s effect as both “about half” and about one-third; the abstract cites ~50% for PA supplementation. Readers should consult the full paper for exact figures and sample sizes, which are not given in the publicly visible summary.
- Not a treatment recommendation: The study does not show that taking PA supplements or probiotics lowers heart risk in humans. Anyone considering changes to cholesterol treatment should speak with a doctor.
What Happens Next
The logical next steps are controlled human studies to test whether raising PA levels or B. uniformis abundance changes cholesterol or plaque in people, and work to confirm safety. No timeline for human trials was reported.
Related Coverage on Vanderbiltreport.com
- Sugar and Antibiotics: Nature Study Links Sweets to Deeper Gut Microbiome Damage
- Heart Failure Statistics 2026: Deaths Are Rising and Younger Adults Are Increasingly Affected
- Fasting Before a Blood Test: New Study of 9.7 Million Results Finds Most Lab Tests Barely Change
Sources
- Yin, C. et al. “A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice,” Nature, Oct. 7, 2026
- Kozlov, M. “Revealed: How this common gut microbe protects against heart disease,” Nature News, Oct. 7, 2026
Publisher Disclaimer: Vanderbiltreport.com publishes news and information for general informational and educational purposes. Information is compiled from sources believed to be reliable, but Vanderbiltreport.com does not guarantee the accuracy, completeness, or timeliness of all information presented. Readers should independently verify information and conduct their own research before making financial, investment, business, or other decisions.
